Literature DB >> 25165194

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Brian M Alexander1, Evanthia Galanis1, W K Alfred Yung1, Karla V Ballman1, James M Boyett1, Timothy F Cloughesy1, John F Degroot1, Jason T Huse1, Bhupinder Mann1, Warren Mason1, Ingo K Mellinghoff1, Tom Mikkelsen1, Paul S Mischel1, Brian P O'Neill1, Michael D Prados1, Jann N Sarkaria1, Abdul Tawab-Amiri1, Lorenzo Trippa1, Xiaobu Ye1, Keith L Ligon1, Donald A Berry1, Patrick Y Wen1.   

Abstract

Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adaptive randomization; biomarkers; clinical trials; glioblastoma

Mesh：

Substances：

Year:  2014        PMID： 25165194      PMCID： PMC4288520          DOI： 10.1093/neuonc/nou154

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  43 in total

Review 1.  Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

Authors:  Brian M Alexander; Patrick Y Wen; Lorenzo Trippa; David A Reardon; Wai-Kwan Alfred Yung; Giovanni Parmigiani; Donald A Berry
Journal:  Neuro Oncol       Date:  2013-07-14       Impact factor: 12.300

Review 2.  Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.

Authors:  Evanthia Galanis; Wenting Wu; Timothy Cloughesy; Kathleen Lamborn; Bhupinder Mann; Patrick Y Wen; David A Reardon; Wolfgang Wick; David Macdonald; Terri S Armstrong; Michael Weller; Michael Vogelbaum; Howard Colman; Daniel J Sargent; Martin J van den Bent; Mark Gilbert; Susan Chang
Journal:  Lancet Oncol       Date:  2012-05       Impact factor: 41.316

3.  Recurrent high-grade glioma.

Authors:  Eudocia C Quant; Jan Drappatz; Patrick Y Wen; Andrew D Norden
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

Review 7.  Trial designs for personalizing cancer care: a systematic review and classification.

Authors:  Parvin Tajik; Aleiko H Zwinderman; Ben W Mol; Patrick M Bossuyt
Journal:  Clin Cancer Res       Date:  2013-06-20       Impact factor: 12.531

8.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Authors:  Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 12.779

9.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.

Authors:  Paul A Northcott; David J H Shih; Marc Remke; Yoon-Jae Cho; Marcel Kool; Cynthia Hawkins; Charles G Eberhart; Adrian Dubuc; Toumy Guettouche; Yoslayma Cardentey; Eric Bouffet; Scott L Pomeroy; Marco Marra; David Malkin; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

10.  DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.

Authors:  Justin M Craig; Natalie Vena; Shakti Ramkissoon; Ahmed Idbaih; Shaun D Fouse; Memet Ozek; Aydin Sav; D Ashley Hill; Linda R Margraf; Charles G Eberhart; Mark W Kieran; Andrew D Norden; Patrick Y Wen; Massimo Loda; Sandro Santagata; Keith L Ligon; Azra H Ligon
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240
View more
  10 in total

1.  Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Authors:  Stuart A Grossman; Karisa C Schreck; Karla Ballman; Brian Alexander
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

2.  Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.

Authors:  Shakti H Ramkissoon; Wenya Linda Bi; Steven E Schumacher; Lori A Ramkissoon; Sam Haidar; David Knoff; Adrian Dubuc; Loreal Brown; Margot Burns; Jane B Cryan; Malak Abedalthagafi; Yun Jee Kang; Nikolaus Schultz; David A Reardon; Eudocia Q Lee; Mikael L Rinne; Andrew D Norden; Lakshmi Nayak; Sandra Ruland; Lisa M Doherty; Debra C LaFrankie; Margaret Horvath; Ayal A Aizer; Andrea Russo; Nils D Arvold; Elizabeth B Claus; Ossama Al-Mefty; Mark D Johnson; Alexandra J Golby; Ian F Dunn; E Antonio Chiocca; Lorenzo Trippa; Sandro Santagata; Rebecca D Folkerth; Philip Kantoff; Barrett J Rollins; Neal I Lindeman; Patrick Y Wen; Azra H Ligon; Rameen Beroukhim; Brian M Alexander; Keith L Ligon
Journal:  Neuro Oncol       Date:  2015-03-09       Impact factor: 12.300

3.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

4.  Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide.

Authors:  Javier Megías; Alba Martínez; Teresa San-Miguel; Rosario Gil-Benso; Lisandra Muñoz-Hidalgo; David Albert-Bellver; Amara Carratalá; Daniel Gozalbo; Concha López-Ginés; María Luisa Gil; Miguel Cerdá-Nicolás
Journal:  Invest New Drugs       Date:  2019-05-11       Impact factor: 3.850

Review 5.  Sunitinib Possible Sex-Divergent Therapeutic Outcomes.

Authors:  Ignacio Segarra; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

6.  Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Authors:  Shyam K Tanguturi; Lorenzo Trippa; Shakti H Ramkissoon; Kristine Pelton; David Knoff; David Sandak; Neal I Lindeman; Azra H Ligon; Rameen Beroukhim; Giovanni Parmigiani; Patrick Y Wen; Keith L Ligon; Brian M Alexander
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

7.  Toward more informative biomarker-based clinical trials in glioblastoma.

Authors:  Howard Colman
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

Review 8.  Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Authors:  Giulio Cabrini; Enrica Fabbri; Cristiana Lo Nigro; Maria Cristina Dechecchi; Roberto Gambari
Journal:  Int J Oncol       Date:  2015-05-29       Impact factor: 5.650

9.  5-Aminolevulinic Acid Hydrochloride (5-ALA)-Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-03-06

Review 10.  Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Authors:  Chris Jones; Matthias A Karajannis; David T W Jones; Mark W Kieran; Michelle Monje; Suzanne J Baker; Oren J Becher; Yoon-Jae Cho; Nalin Gupta; Cynthia Hawkins; Darren Hargrave; Daphne A Haas-Kogan; Nada Jabado; Xiao-Nan Li; Sabine Mueller; Theo Nicolaides; Roger J Packer; Anders I Persson; Joanna J Phillips; Erin F Simonds; James M Stafford; Yujie Tang; Stefan M Pfister; William A Weiss
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.